One in 10 people in America is fighting a rare disease, or a disorder that affects fewer than 200,000 Americans. Although there are more than 7,000 rare diseases that collectively affect more than 350 million people worldwide, it is not profitable for the pharmaceutical industry to develop new therapies to treat the small number of people suffering from each rare condition.
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition. They have fine-tuned a computer-assisted drug repositioning process that can save time and money in helping these patients receive effective treatment.
“Rare diseases sometimes affect such a small population that discovering treatments would not be financially feasible unless through humanitarian and governmental incentives. These conditions that are sometimes left untreated are labeled ‘orphan diseases.’ We developed a way to computationally find matches between rare disease protein structures and functions and existing drug interactions that can help treat patients with some of these orphan diseases,” said Misagh Naderi, one of the paper’s lead authors and a doctoral candidate in the LSU Department of Biological Sciences.
This research will be published this week in the npj Systems Biology and Applications journal, published by the Nature Publishing Group in partnership the Systems Biology Institute.
“In the past, most repurposed drugs were discovered serendipitously. For example, the drug amantadine was first introduced to treat respiratory infections. However, a few years later, a patient with Parkinson’s disease experienced a dramatic improvement of her disease symptoms while taking the drug to treat the flu. This observation sparked additional research. Now, amantadine is approved by the Food Drug Administration as both an antiviral and an antiparkinsonian drug. But, we can not only rely on chance to find a treatment for an orphan disease,” said Dr. Michal Brylinski, the head of the Computational Systems Biology group at LSU.
The Latest on: Drug repositioning
via Google News
The Latest on: Drug repositioning
- Cardiometabolic Drugs Market Dynamics, Segments and Supply Demand 2018-2028 on April 11, 2019 at 6:58 am
Consumers and pharmaceutical companies are engaging in new drug discovery for each indication resulting in cardiovascular problems. There is a present trend of repositioning of drugs in ... […]
- Alkermes touts Aristada efficacy on-par with J&J's market leader on April 10, 2019 at 9:24 am
Alkermes has been repositioning itself, with the company moving its business model from royalty-dependent to direct sales. Part of the strategy involves investing in a few key drugs. They include ... […]
- AONE Presentation to Show How Patient Repositioning Reduces Hospital-Acquired Pressure Injuries (HAPIs) on April 10, 2019 at 5:43 am
The year-long quality improvement project, which implemented an improved patient repositioning program in a 132-bed community hospital, reduced sacrococcygeal HAPIs – one of the most common ... […]
- Innoblative's SIRA™ RFA Electrosurgical Device Receives FDA Clearance on April 9, 2019 at 6:17 am
"The large spherical applicator minimizes subjective repositioning of the device, leading to a more controllable and predictable ablation performance. A device like this hasn't existed before ... […]
- Breast cancer: The promises of old recipes on March 29, 2019 at 5:21 am
Doxorubicin, on the other hand, kills cells that have stopped growing. A combination of great efficacy!" Is drug repositioning the future of pharmacology? Many researchers around the world have ... […]
- Renewed Purpose for Drug Repositioning on March 28, 2019 at 5:00 pm
PHILADELPHIA -- "The most fruitful basis for the discovery of a new drug is to start with an old drug," the Scottish pharmacologist and Nobel laureate James Black once said. A number of speakers at ... […]
- NuMedii’s New Way to ‘De-Risk’ Drug Repositioning Work on March 24, 2019 at 5:00 pm
The NuMedii platform has potentially broad applications, she adds, but repositioning drugs with known safety profiles was the easiest starting point. The timing couldn’t be better, given that the NIH ... […]
- Intravenous-to-Subcutaneous (IV-to-SC) Drug Migration, 2019-2024 Research Report - ResearchAndMarkets.com on March 20, 2019 at 10:01 pm
DUBLIN--(BUSINESS WIRE)--The "Intravenous-to-Subcutaneous Drug Repositioning" report has been added to ResearchAndMarkets.com's offering. As the pace of competition increases within the pharmaceutical ... […]
- Intravenous-to-Subcutaneous Drug Repositioning on March 19, 2019 at 1:42 pm
NEW YORK, March 19, 2019 /PRNewswire/ -- As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug ... […]
via Bing News